Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIK066 dose-finding study in obese or overweight adults
2016-002868-14Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of licogliflozin in obesity and Overweight (9 arms), sponsored by Novartis. Primary endpoint: Percent change from baseline in body weight at 24 weeks. Started Mar 2017; status: completed.
02
Drugs
licogliflozin
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2016-002868-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002868-14.